ADARx Pharmaceuticals Statistics
ADARx Pharmaceuticals (ADRX) Stock Statistics & Valuation Metrics
Total Valuation
ADARx Pharmaceuticals has a market cap or net worth of $1.54B. The enterprise value is $1.24B.
- Market Cap
- $1.54B
- Enterprise Value
- $1.24B
Share Statistics
ADARx Pharmaceuticals has 111,193,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 111,193,440
- Owned by Insiders
- 29.02%
- Owned by Institutions
- 57.69%
Financial Efficiency
ADARx Pharmaceuticals’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -18.45%.
- Return on Equity (ROE)
- 0.36
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- -18.45%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 34.49K
- Profits Per Employee
- -730.88K
- Employee Count
- 100
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ADARx Pharmaceuticals is -5.66. ADARx Pharmaceuticals’s PEG ratio is 0.17.
- PE Ratio
- -5.66
- PS Ratio
- 229.52
- PB Ratio
- 2.60
- Price to FCF
- -15.85
- Price to Operating Cash Flow
- -15.57
- PEG Ratio
- 0.17
Income Statement
In the last 12 months, ADARx Pharmaceuticals had revenue of 3.45M and earned -73.09M in profits. Earnings per share was -0.97.
- Revenue
- 3.45M
- Gross Profit
- 3.45M
- Operating Income
- -88.36M
- Pretax Income
- -73.09M
- Net Income
- -73.09M
- EBITDA
- -86.04M
- Earnings Per Share (EPS)
- -0.97
Cash Flow
In the last 12 months, operating cash flow was -95.97M and capital expenditures -1.36M, giving a free cash flow of -97.34M billion.
- Operating Cash Flow
- -95.97M
- Free Cash Flow
- -97.34M
- Free Cash Flow per Share
- -0.91
Dividends & Yields
ADARx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.39%
- Earnings Yield
- -6.52%
Stock Price Statistics
- Beta
- 3.84
- 52-Week Price Change
- -28.58%
- 50-Day Moving Average
- 17.13
- 200-Day Moving Average
- 17.13
- Relative Strength Index (RSI)
- 34.07
- Average Volume (3m)
- 651.48K
Important Dates
ADARx Pharmaceuticals upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
ADARx Pharmaceuticals as a current ratio of 16.18, with Debt / Equity ratio of -3.83%
- Current Ratio
- 16.18
- Quick Ratio
- 16.18
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.68
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, ADARx Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ADARx Pharmaceuticals EV to EBITDA ratio is -8.63, with an EV/FCF ratio of -9.86.
- EV to Sales
- 142.81
- EV to EBITDA
- -8.63
- EV to Free Cash Flow
- -9.86
- EV to Operating Cash Flow
- -10.00
Balance Sheet
ADARx Pharmaceuticals has $901.01M in cash and marketable securities with $6.46M in debt, giving a net cash position of $894.55M billion.
- Cash & Marketable Securities
- $901.01M
- Total Debt
- $6.46M
- Net Cash
- $894.55M
- Net Cash Per Share
- $8.04
- Tangible Book Value Per Share
- $5.36
Margins
Gross margin is -231.03%, with operating margin of -1692.59%, and net profit margin of -1431.77%.
- Gross Margin
- -231.03%
- Operating Margin
- -1692.59%
- Pretax Margin
- -1431.77%
- Net Profit Margin
- -1431.77%
- EBITDA Margin
- -1655.60%
- EBIT Margin
- -1692.59%
Analyst Forecast
The average price target for ADARx Pharmaceuticals is $35.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $35.00
- Price Target Upside
- 153.26% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 10
- AI Score
- ―

